

# **Mirtazapine Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

#### **SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Mirtazapine Solid Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 2

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Nervous system)

Short-term (acute) aquatic

hazard

Category 3

Long-term (chronic) aquatic

hazard

Category 3

**GHS** label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : H303 May be harmful if swallowed.

H361fd Suspected of damaging fertility. Suspected of

damaging the unborn child.

H373 May cause damage to organs (Nervous system) through

prolonged or repeated exposure if swallowed.

H412 Harmful to aquatic life with long lasting effects.



# **Mirtazapine Solid Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P312 Call a POISON CENTER/ doctor if you feel unwell.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)	
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 10 -< 20	
Starch	9005-25-8	>= 10 -< 20	

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Protection of first-aiders

: May be harmful if swallowed.

Suspected of damaging fertility. Suspected of damaging the

unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides Silicon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice and personal protective

equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces



# Mirtazapine Solid Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

ake care to prevent spins, waste and mil

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

# Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
(+/-)-1,2,3,4,10,14b- Hexahydro-2- methylpyrazino[2,1- a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 μg/m³	Internal	
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal	
Starch	9005-25-8	CMP	10 mg/m <sup>3</sup>	AR OEL	
	Further information: A4 - Not classifiable as a human carcinogen, lung, Dermatitis				
		TWA	10 mg/m³	ACGIH	





Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 51079-00015 Date of first issue: 23.01.2015 4.3 23.03.2020

**Engineering measures** Ensure adequate ventilation, especially in confined areas.

> Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection. Particulates type

Filter type

Hand protection

Material Chemical-resistant gloves

Remarks Choose gloves to protect hands against chemicals depending

> on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before

breaks and at the end of workday.

Eye protection Wear the following personal protective equipment:

Safety goggles

Skin and body protection Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

If exposure to chemical is likely during typical use, provide Hygiene measures

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance powder

Color No data available

Odor No data available

Odor Threshold No data available

рΗ No data available

Melting point/freezing point No data available

Initial boiling point and boiling :

range

No data available



# **Mirtazapine Solid Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

# **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.



ORGANON

# Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

**SECTION 11. TOXICOLOGICAL INFORMATION** 

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

**Acute toxicity** 

May be harmful if swallowed.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 3.200 mg/kg

Method: Calculation method

**Components:** 

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Starch:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Components:** 

Starch:

Test Type : Maximization Test



# **Mirtazapine Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Routes of exposure : Skin contact Species : Guinea pig Result : negative

## Germ cell mutagenicity

Not classified based on available information.

#### Components:

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow Application Route: Oral Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Mouse Application Route : Oral

Exposure time : 18 month(s)

LOAEL : 200 mg/kg body weight

Result : equivocal Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 20 mg/kg body weight

Result : equivocal Target Organs : Liver, Thyroid



# **Mirtazapine Solid Formulation**

ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 51079-00015 Date of first issue: 23.01.2015 4.3 23.03.2020

### Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

#### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Test Type: Fertility/early embryonic development Effects on fertility

Species: Rat

Application Route: Oral

Fertility: LOAEL: 15 mg/kg body weight

Symptoms: Effect on estrous cycle, Increase of early resorp-

tions.

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were

detected.

Effects on fetal development Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the

offspring were detected., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal

experiments.

#### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

#### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Routes of exposure Ingestion

**Target Organs** Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:



# **Mirtazapine Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Species : Rat

LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Nervous system

Symptoms : Tremors

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 13 Weeks

Target Organs : Nervous system, Testis

Symptoms : Tremors

Starch:

Species : Rat

NOAEL : >= 2.000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,

Dizziness, Disorientation

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

**Components:** 

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19,5 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7

mg/l



ORGANON

# **Mirtazapine Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 3,6 mg/l

Exposure time: 31 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0,32 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

# Persistence and degradability

No data available

Bioaccumulative potential

#### **Components:**

# $(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino \cite{2,1-a} pyrido \cite{2,3-c} \cite{2,2-c} benzazepine:$

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 334 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 2,78

Mobility in soil

#### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environ-

mental compartments

: log Koc: 4,48

### Other adverse effects

No data available

# Mirtazapine Solid Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.3
 23.03.2020
 51079-00015
 Date of first issue: 23.01.2015

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

**UNRTDG** 

Not regulated as a dangerous good

**IATA-DGR** 

Not regulated as a dangerous good

**IMDG-Code** 

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **SECTION 15. REGULATORY INFORMATION**

# Safety, health and environmental regulations/legislation specific for the substance or

Argentina. Carcinogenic Substances and Agents

: Not applicable

Registry.

Control of precursors and essential chemicals for the

Not applicable

preparation of drugs.

#### International Regulations

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### **SECTION 16. OTHER INFORMATION**

#### **Further information**

Sources of key data used to compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

### Full text of other abbreviations



# **Mirtazapine Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.3 23.03.2020 51079-00015 Date of first issue: 23.01.2015

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AR OEL : Argentina. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average AR OEL / CMP : TLV (Threshold Limit Value)

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8